Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma
Purpose. It has been reported that Th2 cytokines downregulate antitumor immunity, while activation of type T cells promotes antitumor immunity. The aim of this paper was to evaluate host immunity in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) receiving sorafenib thera...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/607851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566976889749504 |
|---|---|
| author | Hidenari Nagai Takanori Mukozu Daigo Matsui Takenori Kanekawa Masahiro Kanayama Noritaka Wakui Kouichi Momiyama Mie Shinohara Kazunari Iida Koji Ishii Yoshinori Igarashi Yasukiyo Sumino |
| author_facet | Hidenari Nagai Takanori Mukozu Daigo Matsui Takenori Kanekawa Masahiro Kanayama Noritaka Wakui Kouichi Momiyama Mie Shinohara Kazunari Iida Koji Ishii Yoshinori Igarashi Yasukiyo Sumino |
| author_sort | Hidenari Nagai |
| collection | DOAJ |
| description | Purpose. It has been reported that Th2 cytokines downregulate antitumor immunity, while activation of type T cells promotes antitumor immunity. The aim of this paper was to evaluate host immunity in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) receiving sorafenib therapy. Methods. Forty-five adult Japanese LC patients received sorafenib for aHCC between 2009 and 2011 at our hospital. Sorafenib was administered at a dose of 200–800 mg/day for 4 weeks. Blood samples were collected before and after treatment. Results. Eleven patients were treated with sorafenib at 200 mg/day (200 group), 27 patients received sorafenib at 400 mg/day (400 group), and 7 patients were given sorafenib at 800 mg/day (800 group). There was no significant change in the percentage of Th1 cells after treatment in any group. However, the percentages of Th2 cells and regulatory T cells were significantly decreased after treatment in the 400 group and 800 group compared with before treatment, although there was no significant change after treatment in the 200 group. Conclusions. These results indicate that treatment with sorafenib might induce Th1 dominance and prevent the escape of tumor cells from the host immune system in LC patients with aHCC. |
| format | Article |
| id | doaj-art-a2dba44a926243e2b2c393e85b34dbcc |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-a2dba44a926243e2b2c393e85b34dbcc2025-02-03T01:02:37ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/607851607851Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular CarcinomaHidenari Nagai0Takanori Mukozu1Daigo Matsui2Takenori Kanekawa3Masahiro Kanayama4Noritaka Wakui5Kouichi Momiyama6Mie Shinohara7Kazunari Iida8Koji Ishii9Yoshinori Igarashi10Yasukiyo Sumino11Division of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanDivision of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanDivision of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanDivision of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanDivision of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanDivision of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanDivision of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanDivision of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanDivision of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanDivision of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanDivision of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanDivision of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, JapanPurpose. It has been reported that Th2 cytokines downregulate antitumor immunity, while activation of type T cells promotes antitumor immunity. The aim of this paper was to evaluate host immunity in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) receiving sorafenib therapy. Methods. Forty-five adult Japanese LC patients received sorafenib for aHCC between 2009 and 2011 at our hospital. Sorafenib was administered at a dose of 200–800 mg/day for 4 weeks. Blood samples were collected before and after treatment. Results. Eleven patients were treated with sorafenib at 200 mg/day (200 group), 27 patients received sorafenib at 400 mg/day (400 group), and 7 patients were given sorafenib at 800 mg/day (800 group). There was no significant change in the percentage of Th1 cells after treatment in any group. However, the percentages of Th2 cells and regulatory T cells were significantly decreased after treatment in the 400 group and 800 group compared with before treatment, although there was no significant change after treatment in the 200 group. Conclusions. These results indicate that treatment with sorafenib might induce Th1 dominance and prevent the escape of tumor cells from the host immune system in LC patients with aHCC.http://dx.doi.org/10.1155/2012/607851 |
| spellingShingle | Hidenari Nagai Takanori Mukozu Daigo Matsui Takenori Kanekawa Masahiro Kanayama Noritaka Wakui Kouichi Momiyama Mie Shinohara Kazunari Iida Koji Ishii Yoshinori Igarashi Yasukiyo Sumino Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma Clinical and Developmental Immunology |
| title | Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma |
| title_full | Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma |
| title_fullStr | Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma |
| title_full_unstemmed | Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma |
| title_short | Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma |
| title_sort | sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma |
| url | http://dx.doi.org/10.1155/2012/607851 |
| work_keys_str_mv | AT hidenarinagai sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma AT takanorimukozu sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma AT daigomatsui sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma AT takenorikanekawa sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma AT masahirokanayama sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma AT noritakawakui sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma AT kouichimomiyama sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma AT mieshinohara sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma AT kazunariiida sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma AT kojiishii sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma AT yoshinoriigarashi sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma AT yasukiyosumino sorafenibpreventsescapefromhostimmunityinlivercirrhosispatientswithadvancedhepatocellularcarcinoma |